Etalocib

Etalocib
Names
	Preferred IUPAC name 25-Ethyl-14-fluoro-22-hydroxy-82-propyl-3,7,9-trioxa-1,10(1),2(1,4),8(1,3)-tetrabenzenadecaphane-102-carboxylic acid
	Other names LY293111; VML 295
Identifiers
CAS Number	161172-51-6;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL329123;
ChemSpider	154905;
IUPHAR/BPS	2948;
KEGG	D04074;
PubChemCID	177941;
UNII	THY6RIW44R;
CompTox Dashboard(EPA)	DTXSID70167073;
	InChI InChI=1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37) Key: YFIZRWPXUYFCSN-UHFFFAOYSA-N;
	SMILES Fc1ccc(cc1)c4c(O)cc(OCCCOc3cccc(Oc2ccccc2C(=O)O)c3CCC)c(c4)CC;
Properties
Chemical formula	C33H33FO6
Molar mass	544.619g·mol−1
	Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa). verify(what is?) Infobox references

Etalocibis a drug candidate that was under development for the treatment of various types of cancer.^[1]It acts as aleukotriene B4 receptor antagonistand aPPARγ agonist.^[2]

Clinical trials were conducted measuring efficacy for treatment ofnon-small cell lung cancerandpancreatic cancerand the inflammatory conditionsasthma,psoriasis,andulcerative colitis,but were suspended due to lack of efficacy.^[3]

References[edit]

^Jänne, P. A.; Paz-Ares, L; Oh, Y; Eschbach, C; Hirsh, V; Enas, N; Brail, L; von Pawel, J (2014)."Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer".Journal of Thoracic Oncology.9(1): 126–31.doi:10.1097/JTO.0000000000000037.PMID 24346102.
^Adrian, T. E.; Hennig, R; Friess, H; Ding, X (2008)."The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer".PPAR Research.2008:827096.doi:10.1155/2008/827096.PMC2631651.PMID 19190780.
^"Etalocib".Adisinsight.Retrieved31 January2017.

Thisantineoplasticorimmunomodulatory drugarticle is astub.You can help Wikipedia byexpanding it.

[1] Jänne, P. A.; Paz-Ares, L; Oh, Y; Eschbach, C; Hirsh, V; Enas, N; Brail, L; von Pawel, J (2014)."Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer".Journal of Thoracic Oncology.9(1): 126–31.doi:10.1097/JTO.0000000000000037.PMID 24346102.

[2] Adrian, T. E.; Hennig, R; Friess, H; Ding, X (2008)."The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer".PPAR Research.2008:827096.doi:10.1155/2008/827096.PMC2631651.PMID 19190780.

[3] "Etalocib".Adisinsight.Retrieved31 January2017.

[1]

[2]

[3]

v t e PPARTooltip Peroxisome proliferator-activated receptormodulators
PPARαTooltip Peroxisome proliferator-activated receptor alpha	Agonists:15-HETE 15-HpETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Chiglitazar Clofibrate CP-775146 Daidzein DHEA(prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil GW-7647 Lanifibranor Leukotriene B₄ LG-101506 LG-100754 Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone WY-14643 Antagonists:GW-6471 MK-886
PPARδTooltip Peroxisome proliferator-activated receptor delta	Agonists:15-HETE 15-HpETE Arachidonic acid Bezafibrate Daidzein Elafibranor Fonadelpar Genistein GW-0742 GW-501516 L-165,041 Lanifibranor LG-101506 Seladelpar Sodelglitazar Tetradecylthioacetic acid Antagonists:FH-535 GSK-0660 GSK-3787
PPARγTooltip Peroxisome proliferator-activated receptor gamma	Agonists:5-Oxo-ETE 5-Oxo-15-hydroxy-ETE 15-Deoxy-Δ^12,14-prostaglandin J₂ 15-HETE 15-HpETE Aleglitazar Arachidonic acid Balaglitazone Berberine Bezafibrate Cannabidiol Cevoglitazar Chiglitazar Ciglitazone Daidzein Darglitazone Edaglitazone Efatutazone Englitazone Etalocib Farglitazar Genistein GW-1929 Ibuprofen Imiglitazar Indeglitazar Lanifibranor LG-100268 LG-100754 LG-101506 Lobeglitazone Muraglitazar (muroglitazar) nTZDpa Naveglitazar Netoglitazone Oxeglitazar Peliglitazar Pemaglitazar Perfluorononanoic acid Pioglitazone Prostaglandin J₂ Ragaglitazar Reglitazar Rivoglitazone Rosiglitazone RS5444 Saroglitazar Sipoglitazar Sodelglitazar Telmisartan Tesaglitazar Troglitazone SPPARMsTooltip Selective PPARγ modulator:BADGE EPI-001 INT-131 MK-0533 S26948 Antagonists:FH-535 GW-9662 SR-202 T-0070907 Unknown:SR-1664
Non-selective	Agonists:Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators